Deubiquitinating enzymes (DUBs): DoUBle-edged swords in CNS autoimmunity

• Main Authors: Jing Ruan, Dirk Schlüter, Xu Wang
• Format: Article
• Language: English
• Published: BMC 2020-04-01
• Series: Journal of Neuroinflammation
• Subjects: CNS autoimmunity; Multiple sclerosis; Experimental autoimmune encephalomyelitis; Ubiquitination; Deubiquitinating enzymes
• Online Access: http://link.springer.com/article/10.1186/s12974-020-01783-8

Abstract Multiple sclerosis (MS) is the most common autoimmune disease of the CNS. The etiology of MS is still unclear but it is widely recognized that both genetic and environmental factors contribute to its pathogenesis. Immune signaling and responses are critically regulated by ubiquitination, a posttranslational modification that is promoted by ubiquitinating enzymes and inhibited by deubiquitinating enzymes (DUBs). Genome-wide association studies (GWASs) identified that polymorphisms in or in the vicinity of two human DUB genes TNFAIP3 and USP18 were associated with MS susceptibility. Studies with experimental autoimmune encephalomyelitis (EAE), an animal model of MS, have provided biological rationale for the correlation between these DUBs and MS. Additional studies have shown that other DUBs are also involved in EAE by controlling distinct cell populations. Therefore, DUBs are emerging as crucial regulators of MS/EAE and might become potential therapeutic targets for the clinical treatment of MS.